We now show that activated T cell-conditioned medium (TCM) enhanced proliferation and counteracted imatinib-induced apoptosis of CML cells, and addition of a neutralizing anti-IFNγ antibody at least partially inhibited the anti-apoptotic effect. The gene discussed is IFNG; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.